What is Glaukos Corporation's stock symbol?
Glaukos Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."
Where is Glaukos Corporation's stock going? Where will Glaukos Corporation's stock price be in 2017?
7 brokerages have issued twelve-month price targets for Glaukos Corporation's stock. Their forecasts range from $28.00 to $55.00. On average, they anticipate Glaukos Corporation's share price to reach $44.17 in the next year.
When will Glaukos Corporation announce their earnings?
Glaukos Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
What are analysts saying about Glaukos Corporation stock?
Here are some recent quotes from research analysts about Glaukos Corporation stock:
- Stifel Nicolaus analysts commented, "Glaukos' stock has considerably outperformed the market YTD (+29% relative to the S&P). We attribute the strong performance to ongoing positive investor sentiment as well as a better understanding of the pricing power that the company possesses in 2017 due to the favorable Ambulatory Surgical Center (ASC) reimbursement decision that took hold at the beginning of the year. While Glaukos does not plan to provide ASP details, our late January diligence among a small number of iStent physicians unveiled that Glaukos is in the midst of implementing a significant price increase (~40%) among iStent cases performed at the ASC. A price increase of this magnitude implies upside to the Street's current 2017 revenue estimate of $147.5MM (we are at $151.4MME), and our January report laid out a case where 2017 revenue could total $180MM+. As investors have better understood the power of price over the past few weeks, we believe the bar has been raised into the company's 2017 guidance, which will be provided on Wednesday (AMC). In this report, we take a near-term look at what different 2017 revenue guidance levels imply for 2017 iStent volumes based on our ASP diligence. We also take a longer-term look at Glaukos' future earnings power, which we view as significant, and believe will become more evident in 2H17 / 1H18. Simply put, we can see 2019 adjusted EBITDA per share (which we use as a proxy for cash EPS) of $2.23 to $3.33, which does not include future pipeline products such as iDose, or the significant market opportunity associated with the stand-alone Glaucoma market." (2/28/2017)
According to Zacks Investment Research, "Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. " (1/10/2017)
Who owns Glaukos Corporation stock?
Glaukos Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (6.50%), William Blair Investment Management LLC (5.84%), Interwest Venture Management Co. (3.04%), Federated Investors Inc. PA (2.87%), Janus Capital Management LLC (2.79%) and Renaissance Technologies LLC (2.53%). Company insiders that own Glaukos Corporation stock include Aimee S Weisner, Chris M Calcaterra, Jonathan Silverstein, Montreux Equity Partners Iv Lp, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link.
Who sold Glaukos Corporation stock? Who is selling Glaukos Corporation stock?
Glaukos Corporation's stock was sold by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Two Sigma Investments LP, Deerfield Management Co., Employees Retirement System of Texas and Federated Investors Inc. PA. Company insiders that have sold Glaukos Corporation stock in the last year include Chris M Calcaterra, Jonathan Silverstein, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link.
Who bought Glaukos Corporation stock? Who is buying Glaukos Corporation stock?
Glaukos Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., William Blair Investment Management LLC, Janus Capital Management LLC, Artisan Partners Limited Partnership, Russell Investments Group Ltd., Advisory Research Inc., Renaissance Technologies LLC and Broadfin Capital LLC. Company insiders that have bought Glaukos Corporation stock in the last two years include Aimee S Weisner and Richard L Harrison.
How do I buy Glaukos Corporation stock?
Shares of Glaukos Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Glaukos Corporation stock cost?
One share of Glaukos Corporation stock can currently be purchased for approximately $45.50.